Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah

Rhea-AI Summary

Co-Diagnostics (Nasdaq-CM: CODX) said executives will join the World Trade Center Utah trade mission with Utah Governor Cox from April 13–22, 2026 for meetings across Switzerland and Germany.

The itinerary includes site visits to Roche Diagnostics, UBS, Zurich Innovation Park, and attendance at ESCMID Global 2026 in Munich. According to the company, the trip supports international partnerships as Co-Dx prepares a 510(k) submission for a real-time PCR point-of-care platform; the platform is under regulatory review and not yet available for sale.

News Market Reaction – CODX

+3.60%

4 alerts

+3.60% Session close to close

+2.0% Peak Tracked

-6.9% Trough Tracked

$5.40M Market Cap

0.1x Rel. Volume

In the Apr 9 session, CODX gained 3.60%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.0% during that session. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights CODX’s participation in a Utah-led European trade mission and outreach ...

Analysis

This announcement highlights CODX’s participation in a Utah-led European trade mission and outreach at ESCMID Global 2026, aimed at deepening international relationships ahead of a planned 510(k) submission for its Co-Dx PCR platform. Recent history shows multiple strategic moves in India, Saudi Arabia, and South Asia alongside weak financial results and going-concern warnings. Investors may watch for concrete milestones such as regulatory clearances, commercial contracts, and updates on cash resources and operating losses.

Key Figures

Trade mission dates: April 13-22, 2026 510(k) pathway: 510(k) submission Conference year: 2026

3 metrics

Trade mission dates April 13-22, 2026 World Trade Center Utah mission across Switzerland and Germany

510(k) pathway 510(k) submission Planned submission to U.S. Food & Drug Administration for Co-Dx PCR platform

Conference year 2026 ESCMID Global 2026 Congress in Munich for customer and distributor meetings

Historical Context

5 past events · Latest: Apr 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 02	Saudi JV facility	Positive	-4.9%	CoMira JV secured land allocation for Saudi molecular diagnostics facility.
Mar 31	Full-year earnings	Negative	-12.9%	2025 results showed revenue drop, large operating loss and net loss.
Mar 25	TB clinical studies	Positive	-13.2%	Shipped PCR Pro instruments and TB test kits to enable Indian studies.
Mar 20	Territory expansion	Positive	-2.3%	Expanded CoSara commercial territory across South Asia for PCR Pro and tests.
Mar 17	Earnings date set	Neutral	-8.4%	Announced date and webcast details for Q4 and 2025 results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent CODX announcements—often strategically positive—have frequently been followed by negative price reactions, while weak financial results aligned with a selloff.

Recent Company History

Over the past month, CODX has reported several operational and strategic developments, including South Asia distribution expansion, shipment of TB study materials to India, and approval for a Saudi manufacturing site, all tied to its Co-Dx PCR platform and joint ventures. Despite this, shares fell after each of these updates, and also declined on the 2025 earnings release showing sharply lower revenue and a large net loss. Today’s trade-mission news fits into this pattern of strategic outreach amid financial pressure.

Key Terms

molecular diagnostics, real-time pcr, point-of-care, 510(k) submission, +4 more

8 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

real-time pcr medical

"introducing a real-time PCR point-of-care diagnostic platform"

Real-time PCR is a laboratory method that copies and measures specific genetic material (DNA or RNA) as the reaction happens, giving immediate numerical results rather than only an end-point yes/no. For investors, it matters because it underpins fast, sensitive medical tests and research tools; performance, regulatory acceptance, and manufacturing capacity for real-time PCR systems can directly affect demand, revenue potential, and competitive position in the diagnostics and biotech markets.

point-of-care medical

"real-time PCR point-of-care diagnostic platform"

"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.

510(k) submission regulatory

"currently preparing for a 510(k) submission to the U.S. Food & Drug Administration"

A 510(k) submission is a regulatory packet sent to the U.S. Food and Drug Administration showing a medical device is substantially similar to an already-allowed device so it can be marketed without a full, new safety review. For investors, clearance via 510(k) cuts time and cost to bring a device to market and reduces regulatory risk—think of it as proving a new model is close enough to a trusted one to sell it more quickly.

u.s. food & drug administration regulatory

"submission to the U.S. Food & Drug Administration"

The U.S. Food & Drug Administration (FDA) is the federal agency that reviews and approves medicines, medical devices, vaccines, food safety measures and related health products for use in the United States. Investors watch FDA decisions because approvals, rejections or safety warnings can quickly change a company’s sales prospects and stock value—similar to a referee’s call that can determine whether a product can legally enter the market and compete.

clinical microbiology and infectious disease medical

"Congress of the European Society of Clinical Microbiology and Infectious Disease"

The study and medical practice focused on detecting, diagnosing, treating and preventing infections caused by bacteria, viruses, fungi and parasites. Think of it as the hospital’s detective and response team that finds the germ, figures out which medicine will work, and tracks outbreaks so they don’t spread. Investors watch this area because advances or setbacks in tests, drugs, vaccines and infection-control practices can quickly change demand, regulatory reviews, healthcare spending and company revenue.

diagnostic tests medical

"platform for the development of molecular diagnostic tests"

Diagnostic tests are assessments used to evaluate the health or condition of a company or market to identify potential issues or opportunities. They help investors understand underlying strengths or risks, much like a medical check-up reveals health status before symptoms appear. By providing insights into financial stability or vulnerabilities, diagnostic tests support more informed investment decisions.

research and development technical

"leading technology, diagnostics, financial and R&D environments"

Research and development is the work a company does to discover, test and improve new products, services or processes. Think of it as planting seeds for future growth: it costs money now but can create competitive advantages, new revenue streams or regulatory approvals later, so investors watch R&D spending and progress to judge a company's future growth potential and the risk that those investments may or may not pay off.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more

SALT LAKE CITY, April 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company executives will be participating in the latest World Trade Center (WTC) Utah trade mission with Utah Governor Cox and the Governor's Office of Economic Opportunity, taking place April 13-22 in locations across Switzerland and Germany.

"Switzerland and Germany are home to many of the world's leading technology, diagnostics, financial and R&D environments," said Dwight Egan, Chief Executive Officer, Co-Diagnostics, Inc. "We are pleased to be part of this prestigious trade mission and to help further the goals of our community, while strengthening our own international network of strategic partners and advancing important Co-Dx initiatives."

WTC Utah anticipates that the mission will reinforce connections and deepen commercial, diplomatic, and institutional ties in two of Europe's most influential economies. The itinerary is planned to include visits at notable academic and research institutions, as well as networking events and site visits with globally recognized industry leaders like Union Bank of Switzerland ("UBS") and Roche Diagnostics, one of the world's foremost providers of diagnostics systems.

Company executives are expected to largely participate in the Switzerland portion of the trade mission, before traveling to Munich to meet with prospective customers and distributors at the Congress of the European Society of Clinical Microbiology and Infectious Disease ("ESCMID Global") 2026 in Munich, Germany.

The WTC trade mission comes as Co-Dx is reinforcing global relationships in preparation for introducing a real-time PCR point-of-care diagnostic platform, currently preparing for a 510(k) submission to the U.S. Food & Drug Administration, and follows recent announcements related to the Company's international joint ventures in India and the Kingdom of Saudi Arabia.

World Trade Center Utah is the official international business promotion organization for the Governor's Office of Economic Opportunity in the State of Utah and conducts important trade missions around the world, connecting Utah business to global resources.

*The Co-Dx PCR platform (including the PCR Home^®, PCR Pro^®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-executives-to-participate-in-european-trade-mission-with-utah-governor-and-wtc-utah-302737703.html

SOURCE Co-Diagnostics

FAQ

What will Co-Diagnostics (CODX) do on the April 13–22, 2026 trade mission to Switzerland and Germany?

Co-Diagnostics executives will join meetings, site visits, and industry briefings across Switzerland and Germany. According to the company, planned stops include Roche Diagnostics, UBS, Zurich Innovation Park, and networking events tied to ESCMID Global 2026 in Munich.

How does the April 2026 WTC Utah mission affect Co-Diagnostics (CODX) international partnerships?

The mission aims to deepen commercial and institutional ties with European partners. According to the company, executives expect to strengthen strategic relationships and explore distributor and customer opportunities during meetings and site visits.

Will Co-Diagnostics (CODX) attend ESCMID Global 2026 in Munich during the April 2026 trip?

Yes, Co-Diagnostics executives plan to travel to Munich to meet prospective customers and distributors at ESCMID Global 2026. According to the company, most participation will occur during the Switzerland portion before attending the Munich congress.

What product is Co-Diagnostics (CODX) preparing while participating in the April 2026 trade mission?

Co-Diagnostics is preparing a 510(k) submission for a real-time PCR point-of-care diagnostic platform. According to the company, the PCR Home, PCR Pro, mobile app, and tests remain under regulatory review and are not yet for sale.

Does the April 2026 trade mission involve Co-Diagnostics (CODX) commercial deals or joint ventures?

The mission is intended to explore partnerships but does not announce binding deals. According to the company, the trip follows recent international joint venture announcements in India and Saudi Arabia and seeks to advance global relationships.